| Diabetes Mellitus, Non-Insulin-Dependent

Jardiance vs Mounjaro

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Jardiance vs Mounjaro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsMounjaro has a higher rate of injection site reactions vs Jardiance based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Mounjaro but not Jardiance, including UnitedHealthcare

Category

Jardiance

Mounjaro

At A Glance

RouteOral

FrequencyOnce daily

ClassSGLT2 inhibitor

RouteSC injection

FrequencyOnce weekly

ClassGIP/GLP-1 receptor agonist

Indications

Heart failure
Chronic Kidney Diseases
Diabetes Mellitus, Non-Insulin-Dependent

Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Heart failure, Chronic Kidney Diseases 10 mg orally once daily in the morning, taken with or without food.

Diabetes Mellitus, Non-Insulin-Dependent 10 mg orally once daily in the morning, taken with or without food; may increase to 25 mg once daily in patients tolerating 10 mg for additional glycemic control.

Diabetes Mellitus, Non-Insulin-Dependent Start at 2.5 mg SC once weekly; increase to 5 mg after 4 weeks; escalate in 2.5 mg increments every >=4 weeks as needed; max 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older.

Contraindications

Hypersensitivity to empagliflozin or any excipient in JARDIANCE (reactions such as angioedema have occurred)

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known serious hypersensitivity to tirzepatide or any excipient in MOUNJARO

Drug Interactions

416View drug interactions

299View drug interactions

Adverse Reactions

Most common (>=2%) Urinary tract infection, female genital mycotic infections, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, male genital mycotic infections, nausea

Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypoglycemia (with insulin or sulfonylurea), hypersensitivity reactions

Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, skin reactions (rash, urticaria)

Most common (>=5%) Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain

Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration

Postmarketing Anaphylaxis, angioedema, acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, pulmonary aspiration, acute renal failure or worsening of chronic renal failure, alopecia

Pharmacology

Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; it also reduces sodium reabsorption, which may increase tubuloglomerular feedback, reduce intraglomerular pressure, and lower cardiac pre- and afterload.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that selectively binds and activates both receptors, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner, thereby lowering fasting and postprandial glucose, decreasing food intake, and reducing body weight.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Jardiance